1. Home
  2. ATYR vs HRZN Comparison

ATYR vs HRZN Comparison

Compare ATYR & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • HRZN
  • Stock Information
  • Founded
  • ATYR 2005
  • HRZN 2008
  • Country
  • ATYR United States
  • HRZN United States
  • Employees
  • ATYR N/A
  • HRZN N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • HRZN Finance/Investors Services
  • Sector
  • ATYR Health Care
  • HRZN Finance
  • Exchange
  • ATYR Nasdaq
  • HRZN Nasdaq
  • Market Cap
  • ATYR 306.2M
  • HRZN 352.9M
  • IPO Year
  • ATYR 2015
  • HRZN 2010
  • Fundamental
  • Price
  • ATYR $5.22
  • HRZN $7.39
  • Analyst Decision
  • ATYR Strong Buy
  • HRZN Hold
  • Analyst Count
  • ATYR 6
  • HRZN 5
  • Target Price
  • ATYR $20.20
  • HRZN $9.20
  • AVG Volume (30 Days)
  • ATYR 2.5M
  • HRZN 380.6K
  • Earning Date
  • ATYR 08-12-2025
  • HRZN 07-29-2025
  • Dividend Yield
  • ATYR N/A
  • HRZN 17.93%
  • EPS Growth
  • ATYR N/A
  • HRZN N/A
  • EPS
  • ATYR N/A
  • HRZN N/A
  • Revenue
  • ATYR N/A
  • HRZN $98,302,000.00
  • Revenue This Year
  • ATYR $960.85
  • HRZN $1.42
  • Revenue Next Year
  • ATYR $1,283.47
  • HRZN $4.42
  • P/E Ratio
  • ATYR N/A
  • HRZN N/A
  • Revenue Growth
  • ATYR N/A
  • HRZN N/A
  • 52 Week Low
  • ATYR $1.42
  • HRZN $7.12
  • 52 Week High
  • ATYR $5.98
  • HRZN $12.63
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 62.87
  • HRZN 44.78
  • Support Level
  • ATYR $5.02
  • HRZN $7.27
  • Resistance Level
  • ATYR $5.98
  • HRZN $7.62
  • Average True Range (ATR)
  • ATYR 0.45
  • HRZN 0.10
  • MACD
  • ATYR -0.04
  • HRZN 0.02
  • Stochastic Oscillator
  • ATYR 52.94
  • HRZN 46.15

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About HRZN Horizon Technology Finance Corporation

Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.

Share on Social Networks: